Mitosis in human cells is initiated at the end of G2 by activation of the Cdc2/cyclin B complex. Activation occurs by dephosphorylation of the inhibitory residues, threonine 14 (T14) and tyrosine 15 (Y15), on Cdc2 by the Cdc25C phosphatase. Entry into mitosis is regulated by the subcellular relocalization of Cdc2/cyclin B, which is rapidly imported into the nucleus at the end of G2. Here, we show that polo-like kinase 3 (Plk3) is able to phosphorylate Cdc25C primarily on S191, and to a lesser extent on S198 in vitro, both of which are within a nuclear exclusion motif. Following transfection, the S191D Cdc25C mutant leads to an enhanced accumulation of Cdc25C in the nucleus, while the S191A mutant facilitated the Cdc25C nuclear exclusion. Furthermore, translocation of Cdc25C to the nucleus was accompanied by a decrease in Cdc2 phosphorylation on Y15. Plk3-WT overexpression led to a sharp increase in Cdc25C nuclear accumulation, while Plk3-KD overexpression failed to do so. The effect of Plk3 overexpression on Cdc25C was reversed by coexpression of a Plk3 siRNA. These results support a role for the polo kinases in coordinating the translocation and perhaps the timing of both Cdc25C and its target Cdc2/cyclin B to the nucleus upon entry into mitosis.
Introduction
Protein phosphorylation plays a key role in controlling cell cycle progression. Most prominent among the enzymes controlling cell cycle transitions are the cyclin-dependent protein kinases (CDKs) (Norbury and Nurse, 1992; Morgan, 1995) . However, protein kinases that are structurally distinct from CDKs also make important contributions to cell cycle progression. The polo-like kinase family (Plk) represents a growing family of cell cycle regulatory kinases. Family members are found in most, if not all, eukaryotic cells, including four mammalian polo-like kinases, Plk1, 2, 3 and 4 (Golsteyn et al., 1996) . In Xenopus Plx1, the homologue of Plk1 phosphorylates Cdc25 on serine and threonine residues, leading to activation of its phosphatase activity (Kumagai and Dunphy, 1996) . Prevention of Plx1 kinase activation by its immunodepletion suppresses hyperphosphorylation of Cdc25C and the consequent activation of Cdk1-cyclin B kinase in Xenopus egg extracts (Abrieu et al., 1998) . The human Plk1 is activated simultaneously with Cdc2/cyclin B during the G2/M transition (Golsteyn et al., 1995) . Plk1 was identified as a protein that phosphorylates a serine residue (S147) in the nuclear exclusion signal (NES) of cyclin B and targets it to the nucleus during prophase in vertebrate cells. It has been argued that Plk1-mediated phosphorylation is responsible for inactivating the NES of cyclin B rather than enhancing the nuclear import of cyclin B (Toyoshima-Morimoto et al., 2001) .
Entry into mitosis also depends on phosphorylation and activation of the dual specificity phosphatase Cdc25C, which dephosphorylates and activates the Cdc2/cyclin B complex that catalyses the G2/M transition (Gautier et al., 1991; Izumi et al., 1992; Kumagai and Dunphy, 1992; Hoffmann et al., 1993) . In mammals, the Cdc25 family includes three homologues, Cdc25A, B and C (Sadhu et al., 1990; Galaktionov and Beach, 1991; Nagata et al., 1991) . Cdc25B and C are regarded as mitotic regulators (Nilsson and Hoffmann, 2000) and serve as targets of checkpoint pathways that delay entry into mitosis in response to DNA damage or stalled replication (Bulavin et al., 2001) . Cdc25B is probably the phosphatase that triggers the initial activation of mitosis-promoting CDKs including Cdc2/ cyclin B, which in turn activate Cdc25C and create a positive amplification loop required for irreversible commitment to mitosis (Nilsson and Hoffmann, 2000) . Cdc25C is predominantly cytoplasmic during G1 and S phases in a variety of cell lines (Dalal et al., 1999; Graves et al., 2000) . Its exclusion from the nucleus is dependent on the export protein CRM1 as suggested by its nuclear accumulation upon treatment with leptomycin B (LMB) (Graves et al., 2001) . Nuclear import of Cdc25C was reported to be induced following the phosphorylation of S198 by Plk1 (Toyoshima-Morimoto et al., 2002) . Human Cdc25C is phosphorylated on serine 216 (S216) and bound to 14-3-3 proteins throughout interphase (Peng et al., 1997) . Phosphorylation of S216 is required for 14-3-3 binding, and mutation of S216 to alanine abrogates 14-3-3/Cdc25C interaction (Peng et al., 1997) . Intrinsic nuclear import and export signals, together with 14-3-3 binding, appear to regulate coordinately the intracellular trafficking of Cdc25C (Graves et al., 2001) .
We now show that Plk3 is able to regulate Cdc25C translocation to the nucleus by phosphorylating primarily S191 and to a much lesser extent S198, both of which reside within a functional NES (Graves et al., 2001) . Furthermore, S191 phosphorylation of Cdc25C is accompanied by a decrease in Y15 phosphorylation on Cdc2. Transfection of cells with GFP-Plk3-WT, but not GFP-Plk3-KD, led to Cdc25C accumulation in the nucleus. Reduction of Plk3 mediated by Plk3 siRNA reversed the nuclear accumulation of Cdc25C. Thus, phosphorylation by members of the Plk family of both Cdc25C and its target Cdc2/cyclin B complex and their apparent concomitant nuclear translocation may help regulate the transition from G2 to mitosis.
Results

Plk3 cofractionates and immunoprecipitates with Cdc25C
In Xenopus extracts, Plx1 exists in a complex with Cdc25C (Kumagai and Dunphy, 1996) . In order to assess whether Plk3 forms a complex with Cdc25C in mammalian cells, lysate from HeLa cells, synchronized in prometaphase using 100 ng/ml nocodazole, was size fractionated using FPLC and a Superdex 200 column. An aliquot from each fraction was tested for the presence of Plk3 and Cdc25C by Western Blot (Figure 1a ). Both a phosphorylated form of Plk3 and a phosphorylated form of Cdc25C were detected in the same fractions (8 and 9) with a molecular weight of about 600 kDa, suggesting that these two proteins may be part of the same complex ( Figure 1a) . In order to address this possibility, Plk3 was tested to determine whether it could coimmunoprecipitate with Cdc25C using cells transfected with GFP plasmid alone or with a GFP-Cdc25C plasmid. GFP and GFP-Cdc25C fusion proteins were immunoprecipitated with antibody to GFP and immunocomplexes were probed for the presence of Plk3 by Western blot. As shown in Figure 1b , GFP-Cdc25C but not GFP coimmunoprecipitates with a phosphorylated form of Plk3 from transfected cells, demonstrating that Cdc25C and Plk3 form a stable complex in vivo.
Plk3 phosphorylates Cdc25C in vitro
The interaction of Cdc25C and Plk3 suggested that Cdc25C might be a substrate for Plk3. To test this hypothesis, glutathione transferase (GST)-Plk3 and GST-Cdc25C were purified from bacteria and in vitro kinase assays were performed. Figure 2a shows that the full-length Cdc25C is phosphorylated by Plk3; this result confirms previous work by Ouyang et al. (1999) , suggesting that Plk3 phosphorylates Cdc25C. To extend these data, we made a series of deletion mutants of Cdc25C covering either the region containing S216 or the N-terminal portions of Cdc25C containing an NES motif (GST-Cdc25C (1-195)) or (GST-Cdc25C (1-205)) recently reported to be phosphorylated by Plk1 (Toyoshima-Morimoto et al., 2002) .
The Plk3 kinase phosphorylated Cdc25C (1-195) and Cdc25C (1-205) fragments, but not the Cdc25C (200-256) fragment, which contains the S216 residue (Figure 2a and b) . This is in contrast to a previous report (Ouyang et al., 1999) . The Cdc25C (1-195) fragment containing the S191 residue was intensely phosphorylated by Plk3 and its mutation from serine to alanine led to a complete abolition of its phosphorylation ( Figure 2b ). When S191 was mutated to alanine in the longer Cdc25C (1-205) fragment, a very weak phosphorylation was detected. Similar results were obtained when Cdc25C deletion mutants were used as maltosebinding protein (MBP) fusion proteins (data not shown). These results suggest that the main phosphorylation site on Cdc25C by Plk3 in vitro is S191, while S198 is a minor phosphorylation site.
Phosphorylation of Cdc25C on S191 leads to its accumulation in the nucleus
Both S191 and S198 are part of a functional NES in Cdc25C (Graves et al., 2000) . In order to analyse the effect of phosphorylation at these sites on Cdc25C localization, we generated GFP-Cdc25C fusion proteins carrying alanine or aspartic acid residues at each of these serine residues. Single mutants S191A, S198A, GFP-transfected cells and GFP-Cdc25C full-length transfected cells were lysed and the lysates were used for immunoprecipitation using GFP antibody. Whole-cell lysate was used as a positive control for Plk3 expression. HC refers to IgG heavy chain S191D or S198D as well as double mutants S191A, 198A or S191D, 198D were constructed as GFPCdc25C fusion proteins. Wild-type and mutant constructs were transfected into HT-1080 cells and localization of GFP was visualized by confocal microscopy and the proportion of GFP-Cdc25C expressing cells displaying nuclear exclusion (i.e. absence of fluorescence in the nucleus) was determined. As shown in Figure 3a , Cdc25C-WT was excluded from the nucleus in a majority of cells. The S191D mutant caused a complete loss of nuclear exclusion, while the S191A mutant had minimal nuclear exclusion effect. The S198A and S198D mutants both showed a statistically significant inhibition of nuclear exclusion, which may be due to the destabilization of the NES rather than the phosphorylation status of the residue. Similar analysis of the double mutants, S191A, 198A and S191D, 198D, replicated the results, indicating that S198 mutation to either A or D destabilizes the NES. These data support Plk3 phosphorylation of S191 but not S198 as a mechanism to negate the NES function, resulting in the accumulation of Cdc25C in the nucleus.
Reduction of Plk3 by siRNA reverses the Cdc25C nuclear accumulation
In order to establish a direct link between Plk3 and nuclear accumulation of Cdc25C, siRNA oligos corresponding to unique regions of Plk3 were used to diminish Plk3 expression in vivo. Cells were transfected with either GFP-Plk3, GFP-Plk3-KD or cotransfected with GFP-Plk3-WT and either siRNA1 or siRNA2, both of which are unique to Plk3 as well as with a scrambled siRNA oligo (data not shown). Figure 4a shows that both siRNAs are able to reduce the HT-1080 cells were transfected with (a) GFP-Cdc25C, GFPCdc25C S191A, GFP-Cdc25C S191D as well as GFP-Cdc25C S198A, GFP-Cdc25C S198D, and the double mutants GFPCdc25C 191, 198D . The proportion of GFP expressing cells that displayed nuclear exclusion was assessed for a total of four fields per sample. N480. (b) HT-1080 cells were transfected with GFP-Cdc25C, GFP-Cdc25C S191A or GFP-Cdc25C S191D. After 16 h green fluorescence was visualized by confocal microscopy expression of GFP-Plk3 by up to 85% by 16 h after transfection. The expression of Plk1 was not affected by these SiRNAs (Figure 4a ), attesting to their specificity. To better understand the role of Plk3 in regulating Cdc25C localization; we transfected cells with GFP alone, GFP-Plk3 WT and GFP-Plk3 KD or with both GFP-Plk3 WT and siRNA1 and fractionated the cells into cytoplasmic and nuclear fractions. We then probed each fraction for Cdc25C in the different backgrounds described above. Fra1 protein, a transcription factor localized exclusively in the nucleus, was used as a nuclear marker. As shown in Figure 4b , Cdc25C is mainly cytoplasmic in cells transfected with GFP alone. Cells transfected with GFP-Plk3 WT showed a shift in Cdc25C localization to the nucleus, while GFP-Plk3 KD failed to induce such a change in localization. The Cdc25C accumulation in the nucleus was reversed by siRNA directed at Plk3, indicating that Plk3 phosphorylation of Cdc25C leads to its nuclear translocation. The scrambled siRNA had no effect on Cdc25C localization (data not shown).
Discussion
In eukaryotic cells, initiation of mitosis requires the activation of M phase promoting factor (MPF). The kinase activity of Cdc2/cyclin B is controlled by the phosphorylation state of Cdc2 and the accumulation of cyclin B. In addition to cyclin B accumulation and phosphorylation status of Cdc2, intracellular localization of cyclin B is also regulated during the progression of the cell cycle (Pines, 1999) . In interphase, cyclin B resides in the cytoplasm due to its NES-dependent nuclear export (Toyoshima et al., 1998; Dalal et al., 1999) . At the G2/M transition, cyclin B becomes phosphorylated causing its translocation to the nucleus (Toyoshima-Morimoto et al., 2001; Yang et al., 2001) . The nuclear accumulation of active MPF is thought to be important for initiating and coordinating M phase events in vertebrate cells (Takizawa and Morgan, 2000) . The activity of Cdc25C progressively increases during the G2-M transition and this activation correlates with hyper-phosphorylation in its N-terminal region (Izumi and Maller, 1993) . Therefore, the nuclear accumulation of Cdc25C appears to play an essential role in maintaining the activity of MPF in the nucleus during prophase by counteracting the inhibitory activity of the Wee1 kinase.
Our results suggest that Plk3 phosphorylation of Cdc25C on S191 is central to inducing its nuclear translocation. Plk3 strongly phosphorylated Cdc25C on S191 in vitro, and mutation of S191 to A led to loss of the phosphorylation of the 1-195 fragment. Significantly, S191 is within a previously described functional Cdc25C NES. In order to test whether intracellular localization of Cdc25C can be affected by Plk3 phosphorylation of S191, we constructed GFP-Cdc25C and either its S191A or S191D mutants and followed their intracellular localization by green fluorescence. While S191D increased the nuclear localization of Cdc25C, the S191A mutant did not. The S198 residue was weakly phosphorylated by Plk3 in vitro and its mutation to either D or A only slightly affected Cdc25C localization in vivo. Thus, mutation of S198 leads only to a slight inactivation of the NES regardless of the phosphomimetic status of the residue. Mutation of S191 to D and Cdc25C translocation to the nucleus correlated with a decrease in Y15 phosphorylation on Cdc2 (data not shown). This finding is consistent with a role for Cdc25C in maintaining active nuclear MPF by counteracting the inhibitory activity of Wee1, which is constitutively nuclear. The recent report that Plk1 phosphorylates S147 in the middle of the NES of cyclin B and targets it to the nucleus during prophase (Toyoshima-Morimoto et al., 2001) suggests that polo kinases may play a central role in coordinating the nuclear translocation of both Cdc25C and its target Cdc2/cyclin B to the nucleus. The timing of this translocation may be essential for coordinating M phase events.
Plk3 was previously reported to phosphorylate Cdc25C on S216 (Ouyang et al., 1999) . We were unable to reproduce this finding using bacterially expressed proteins in vitro. A possible explanation for the previous finding was the use of immunoprecipitated Plk3 for the kinase reactions. Others and we have recently shown that both Plk3 and Plk1 interact with and immunoprecipitate Chk2 (Bahassi et al., 2002; Tsvetkov et al., 2002) . Thus, the former observation that Plk3 immunocomplex phosphorylates S216 on Cdc25C may be due to the coimmunoprecipitated Chk2 or other kinase rather than Plk3 itself.
Further compelling evidence linking Plk3 to Cdc25C accumulation in the nucleus derives from the overexpression of Plk3 WT. Transfection of cells with Plk3 Lysates from cells transfected with GFP alone, GFP-Plk3-WT, or GFP-Plk3-KD, or cotransfected with both GFP-Plk3 and siRNA targeted to Plk3 were fractionated into cytoplasmic and nuclear fractions, and extracts were probed for Cdc25C. Fra1 was used as a nuclear marker
Wt but not with Plk3 KD resulted in a marked increase of Cdc25C in the nuclear fraction following cell fractionation. This nuclear accumulation was inhibited when Plk3 was suppressed by siRNA, implicating Plk3 in the nuclear accumulation of Cdc25C. Despite recent progress, our understanding of overlapping and unique roles of the Cdc25 phosphatases and their activating kinases at various cell cycle transitions is incomplete. One crucial question has emerged from the finding that homozygous disruption of Cdc25C in mice yielded healthy animals whose cells suffered no mitotic defect, had no alteration of Cdc2 phosphorylation and responded normally to DNA damage (Chen et al., 2001) . Cdc25A is a plausible candidate that may compensate for the Cdc25C loss. Cdc25A was recently shown to bind and activate Cdc2/cyclin B, and to accelerate cell division when overexpressed (Chen et al., 2001) . Conversely, its downregulation delayed mitotic entry (Mailand et al., 2002) . Plk3 is able to phosphorylate Cdc25A in vitro (Myer et al., unpublished data) and it is possible that Plk3 regulates Cdc25A nuclear translocation as well. It appears, therefore, that the Plk family may be one of the key regulators of the Cdc25 phosphatases.
Materials and methods
Cell culture and transfection
HeLa cells and HT1080 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (Eurobio), 2 mM glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml) in a humidified atmosphere containing 5% CO 2 at 371C. Transfections were achieved using either lipofectamine 2000 (Invitrogen) or FuGENE 6 (Roche) following the manufacturer's recommendations.
Cell lysis, immunoprecipitation and Western blotting
Cells were harvested 24 h after transfection and lysed in icecold lysis buffer (50 mM HEPES, pH 7.0, 250 mM NaCl, 0.2% Nonidet P-40, 10% (vol/vol) glycerol, 1 mM NaVO 4 , 1 mM DTT) freshly supplemented with 1 mM PMSF, 10 mg/ml aprotinin, pepstatin and leupeptin. Cell lysates were incubated on ice for 1 h with occasional mixing. Subsequently, 20 ml of protein A/G plus-agarose beads (Santa Cruz Biotechnology) were added and lysates were precleared by centrifugation for 5 min at 2000 g. The supernatant was incubated for 3 h at room temperature with 2 mg of GFP antibody (Santa Cruz), p34Cdc2 antibody (PharMingen) or 2 mg mouse or rabbit IgG (negative control), followed by the addition of protein A/G plus-agarose beads and incubating for further 30 min. Recovered beads were washed four times, boiled for 5 min in sample buffer and loaded on a 10% SDS-PAGE. Precipitated proteins were analysed by Western blotting using Cdc2 Tyr15 phosphospecific antibody (Cell Signaling Technologies), Plk3 monoclonal antibody (BD) or antibody to GFP.
Expression and purification of GST-fusion proteins BL21 E. coli cells were transformed with the following plasmids: pGEX2T, pGEX2T-Plk3, pGEX2T-Plk3 KD , pGEX2T-Cdc25C, pGEX2T-Cdc25C (200-256), pGEX2T-Cdc25C (1-195), pGEX2T-Cdc25C (1-205), pGEX2T-Cdc25C (1-195, S191/ A), pGEX2T-Cdc25C (1-205, S191/A) and pGEX2T-Cdc25C (1-205, S198/A). Cultures were grown at 371C to an A 600 of 0.8 and IPTG was added to a final concentration of 0.5 mM. After growing for an additional 3 h at 301C, cells were pelleted by centrifugation. Cell pellets were washed with PBS and were resuspended in STE (10 mM Tris HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA) supplemented with 2 mM DTT, 1 mg/ml lysozyme and protease inhibitors (2 mM PMSF, 0.15 U/ml aprotinin, 20 mM leupeptin, 20 mM pepstatin). Cells were incubated on ice for 1 h with occasional mixing. Lysates were clarified by centrifugation (13 000 g for 15 min) and Triton X-100 was added to a final concentration of 2%. GST fused proteins were sedimented after binding with GST-agarose beads (Sigma Chemical Co.) and washed three times with STE buffer. Protein was eluted from GSH-agarose with 20 mM glutathione and 1 mM DTT in PBS.
In vitro kinase reactions
Protein kinase activities were assayed by incubation with substrates at 371C for 1 h in 1 Â kinase buffer (30 mM HEPES pH 7.4, 10 mM MgCl 2 and 1 mM DTT) supplemented with 10 mM nonradioactive ATP and 10 mCi of [g] 32 P-ATP (Amersham Pharmacia Biotech). Kinase reactions were extinguished by the addition of 6 Â SDS loading buffer, boiled for 10 min and fractionated by SDS-PAGE on 10% acrylamide gel.
Protein fractionation by gel filtration
Analytical gel filtration was performed using a Superdex-200 FPLC column (Amersham Pharmacia Biotech.) in a buffer containing 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl at a flow rate of 0.5 ml/min. Molecular weight markers used to calibrate the column were: thyroglobulin (670 000), ferritin (440 000), g-globulin (158 000), bovine serum albumin (67 000) and ovalbumin (43 000). A measure of 0.5 ml fractions were collected; about 20 mg protein from each fraction was resolved on a 10% SDS-PAGE and immunoblotted.
Plasmid construction and site-directed mutagenesis GFP-Cdc25C plasmid was constructed by PCR-amplifying the full-length Cdc25C cDNA from pGEX2T-Cdc25C (a gift from Dr Y Sanchez, University of Cincinnati) and cloned into XhoI/HindIII sites in pEGFP-C1 (Clontech). Site-directed mutagenesis of the full-length Cdc25C gene was performed by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The Cdc25C deletion mutants were generated by PCR using the full-length Cdc25C as a template and primers containing EcoRI and BamHI sites and subsequent cloning into pGEX2T.
Confocal microscopy
To visualize GFP fluorescence, cells were plated on 24 mm coverslips and transfected as described above. After 16 h, the cells were fixed with 4% paraformaldehyde in PBS for 15 min at room temperature and mounted with Gelmount (Fisher). Images were acquired with a Zeiss LSM510 laser scanning confocal microscope fixed to a Zeiss Axioplan upright microscope using a 63 Â 1.2 N.A. water immersion objective.
mRNA depletion by siRNA
The pSilencert siRNA Expression Vector (Ambion) was used for inducing RNA interference (RNAi) by the expression of small interfering RNA (siRNA) (Elbashir et al., 2001 ). The sequences of Plk3 siRNA1 and siRNA2 oligonucleotides corresponding to unique regions of Plk3 were CGGCCT CATGCGCACATCC and CTGCGTGACAGTCCCAGAC, respectively. The control siRNA used was provided by Ambion. Cells were transfected with pSilencer siRNA by using Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions.
Cell fractionation
Cells were washed three times with cold PBS, and resuspended in 0.5 ml of hypotonic buffer (10 mM Tris pH 7.4, 10 mM NaCl, 1.6 mM MgCl 2 , 1 mM CaCl 2 , 0.1% Triton X-100, 5 mM DTT, Protease Inhibitor Cocktail (Sigma)]. Cells were homogenized with 30-50 strokes of the dounce homogenizer on ice and the nuclei were pelleted at 1000 g for 2 min at 41C. The nuclei were resuspended in 0.5 ml storage buffer (20 mM HEPES pH 8.0, 500 mM KCl, 5 mM MgCl 2 , 20 Glycerol, Protease Inhibitor Cocktail (Sigma)). After incubation on ice for 30 min, the solution was pelleted at 15 000 r.p.m. (21 000 g) for 10 min at 41C.
